Muscle degeneration without mechanical injury in sarcoglycan deficiency

  1. A. A. Hack*,,
  2. L. Cordier,
  3. D. I. Shoturma,
  4. M. Y. Lam,
  5. H. L. Sweeney, and
  6. E. M. McNally,§
  1. *Department of Molecular Genetics and Cell Biology and Department of Medicine, Section of Cardiology, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637; and Department of Physiology, A700 Richards Building, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6085
  1. Edited by Louis M. Kunkel, Harvard Medical School, Boston, MA, and approved July 21, 1999 (received for review April 29, 1999)

Abstract

In humans, mutations in the genes encoding components of the dystrophin–glycoprotein complex cause muscular dystrophy. Specifically, primary mutations in the genes encoding α-, β-, γ-, and δ-sarcoglycan have been identified in humans with limb-girdle muscular dystrophy. Mice lacking γ-sarcoglycan develop progressive muscular dystrophy similar to human muscular dystrophy. Without γ-sarcoglycan, β- and δ-sarcoglycan are unstable at the muscle membrane and α-sarcoglycan is severely reduced. The expression and localization of dystrophin, dystroglycan, and laminin-α2, a mechanical link between the actin cytoskeleton and the extracellular matrix, appears unaffected by the loss of sarcoglycan. We assessed the functional integrity of this mechanical link and found that isolated muscles lacking γ-sarcoglycan showed normal resistance to mechanical strain induced by eccentric muscle contraction. Sarcoglycan-deficient muscles also showed normal peak isometric and tetanic force generation. Furthermore, there was no evidence for contraction-induced injury in mice lacking γ-sarcoglycan that were subjected to an extended, rigorous exercise regimen. These data demonstrate that mechanical weakness and contraction-induced muscle injury are not required for muscle degeneration and the dystrophic process. Thus, a nonmechanical mechanism, perhaps involving some unknown signaling function, likely is responsible for muscular dystrophy where sarcoglycan is deficient.

Footnotes

  • § To whom reprint requests should be addressed at: Department of Medicine, Section of Cardiology, The University of Chicago, 5841 South Maryland Avenue, MC 6088, Chicago, IL 60637. E-mail: emcnally{at}medicine.bsd.uchicago.edu.

  • This paper was submitted directly (Track II) to the Proceedings Office.

  • ABBREVIATIONS:
    DGC,
    dystrophin–glycoprotein complex;
    DMD/BMD,
    Duchenne/Becker muscular dystrophy;
    LGMD,
    limb-girdle muscular dystrophy;
    ECC,
    eccentric contraction;
    EDL,
    extensor digitorum longus
« Previous | Next Article »Table of Contents